

Advanced Therapies Week 2025 Agenda Reveals Provocative Sessions on Biotech Investment, Regulatory Shifts, and Patient-Centered Innovation

A diverse lineup of speakers and industry experts are scheduled to address emerging industry trends, funding challenges, and the future of cell and gene therapy in Dallas from January 20–24 2025.

Dallas, Texas; November 14, 2024 — Phacilitate, the award-winning team behind Advanced Therapies Week 2025, has released the full agenda for the January event that addresses the evolving landscape of cell and gene therapy, providing an in-depth and provocative look at investment trends, regulatory developments, technological advancements, and patient-centered approaches.

"The Advanced Therapies Week 2025 agenda captures the pulse of an industry in transformation," said Ryan Leahy, VP of Research. "This time out, we're addressing not just the breakthroughs in cell and gene therapies, but also the essential discussions around funding, patient engagement, technical revolution and regulatory evolution that drive sustainable progress. Our aim, as always, is to provide a space where leaders across biotech can engage with both challenges and opportunities, paving the way for treatments that truly impact patient lives."

The Advanced Therapies Week 2025 agenda comprises six tracks amongst many other unique features, characteristic of a Phacilitate event. The key topics reflect pertinent trends and areas for urgent conversation, including but not limited to the gradual recovery of investment in biotech, regulatory agency collaboration, therapeutic expansion into new indications, technological advancements to reduce patient costs, and greater involvement of patient advocacy in development.

A diverse lineup of speakers and industry experts has been announced agenda-wide, with highlights including:

- Eytan Breman, Head of Research & Development, Celyad
- Nathan Moore, Head, Cell Therapy Technologies and Digital Transformation, Takeda
- Anthony Davies, Dark Horse Consulting Group
- Bo Wiinberg, Chief Business Officer, Cellerator
- Kasia Averall, Vice President of Quality, Quell Tx

Featured events running alongside the core agenda also include the Women in Advanced Therapies and Investment Summits, enabling focused and direct discussion, collaboration and networking opportunities, following an incredibly successful initial meeting at Advanced Therapies Week 2024.

"As we unveil the agenda for Advanced Therapies Week 2025, we're reminded of the immense strides this community continues to make in delivering advanced therapies that improve lives," said Kim Barnes, President of Phacilitate. "This event brings together the brightest minds and innovative companies, providing a unique platform for meaningful dialogue, collaboration, and inspiration. We're excited to see the groundbreaking ideas and connections that will come from this year's event."

Celebrating over two decades as the leading event for the advanced therapies community, the annual event is next due to be held in Dallas from January 20–24 2025, and is expected to bring together top innovators from across the cell and gene therapy ecosystem, including 400 biotechnology leaders, as well as investors, regulators, and patient advocates, to discuss challenges and progress in delivering advanced treatments.

Phacilitate encourages potential attendees to take advantage of early bird ticket pricing, available through November 22.

For more information and to view the full agenda, please visit advancedtherapiesweek.com or contact team@phacilitate.com.

About Phacilitate and Advanced Therapies Week

Phacilitate is dedicated to improving patient outcomes by supporting the development and delivery of life-changing treatments. By fostering collaboration among key players in advanced therapies, Phacilitate accelerates the commercialization journey for biotechs. Advanced Therapies Week is the flagship event, organized by Phacilitate, that brings this mission to life, convening thousands of leaders, innovators, and decision-makers each year to transform the future of healthcare.